CINC News and Press, CinCor Pharma Inc. From 03/22/22

BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer ...

As part of the quarterly initial public offering (IPO) additions, CinCor Pharma (NASDAQ:CINC) will join the Russell 2000 and Russell 3000 Indexes, effective Mar. 18, 2022. In early 2022, the biopharmaceutical company filed to offer 12.1M shares of its common stock at $16/share, for expected g...

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that the Company will be a...

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fo...

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team wi...

Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...

Shares of CinCor Pharma Inc. (NASDAQ:CINC) traded at a new 52-week high today of $28.75. This new high was reached on below average trading volume as 101,000 shares traded hands, while the average 30-day volume is approximately 196,000 shares. CinCor Pharma Inc is a clinical-stage biopha...

Vancouver, Kelowna, Delta, BC - February 25, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Cannabis and Mining. Today's stocks have been added to our lists of free sto...

Shares of CinCor Pharma Inc. (NASDAQ:CINC) traded today at $25.20, eclipsing its 52-week high. So far today approximately 101,000 shares have been exchanged, as compared to an average 30-day volume of 271,000 shares. CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused...

The biotech sector is also presenting exciting opportunities for investors. Many of the best biotech companies have both strong drug candidate pipelines and winning drugs already on the market. The COVID-19 pandemic has also created massive opportunities for biotechnology companies. According...